The shot is the lead product candidate from BioNTech's FixVac platform and is based on a combination of four mRNA-encoded, ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer ...

Cognition Therapeutics has reported phase 2 data with its Alzheimer's disease candidate, claiming the results show ...

“Advanced AI models are enabling the delivery of more personalised scientific communications,” noted McGregor. “In the ...

Boehringer Ingelheim has bought Nerio Therapeutics, saying that it is adding a programme that – while still in preclinical ...

The GSK deal is another endorsement of Flagship's strategy of creating companies based on biopharma technology platforms, ...

Enhertu was approved for this indication on the strength of the DESTINY-Breast 04 trial, which found that the drug offered an ...

The CHMP decision follows a similar verdict on Eisai and Biogen's first amyloid-targeting drug Aduhelm (aducanumab), which ...

"Depression is a significant challenge for the NHS in England, representing a substantial portion of the overall disease ...

The BROOKLYN study compared the oral CETP inhibitor to a placebo given on top of maximum tolerated doses of other ...

AstraZeneca's Calquence has hit the mark in the phase 3 AMPLIFY trial in chronic lymphocytic leukaemia (CLL), a study that ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic ...